Tevogen Bio regains Nasdaq bid-price compliance

Tevogen Bio Holdings Inc. reports that it has regained compliance with the Nasdaq minimum bid price requirement for continued listing on the Nasdaq Global Market.

Rhea-AI Filing Summary

Tevogen Bio Holdings Inc. reports that it has regained compliance with the Nasdaq minimum bid price requirement for continued listing on the Nasdaq Global Market. Nasdaq confirmed this status in a written notice dated March 20, 2026, and the matter is described as closed.

The company regained compliance after implementing a 1-for-50 reverse stock split of its common stock, which became effective on March 6, 2026. Tevogen’s common stock and warrants continue to trade on Nasdaq under the symbols TVGN and TVGNW.

Insights

Equity Markets & Listing Standards Analyst

Tevogen restores Nasdaq bid-price compliance via 1-for-50 reverse split.

Tevogen Bio Holdings Inc. has confirmed compliance with Nasdaq’s minimum bid price rule after executing a 1-for-50 reverse stock split effective March 6, 2026. Nasdaq’s written notice on March 20, 2026 states that the listing matter is closed.

This development removes the immediate risk of delisting based on bid price, which can help maintain liquidity and visibility associated with a Nasdaq Global Market listing. The reverse split is a structural change to the share count and trading price, without adding new capital or altering total equity value.

Future company filings may provide additional context on how the adjusted share structure interacts with trading volume, institutional interest and any ongoing strategic or financing plans following the restored compliance status.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tevogen Bio Holdings Inc. (TVGN) announce in this 8-K?

Tevogen Bio Holdings Inc. announced it has regained compliance with Nasdaq’s minimum bid price requirement for continued listing on the Nasdaq Global Market, following a 1-for-50 reverse stock split of its common stock effective March 6, 2026.

How did Tevogen Bio (TVGN) regain compliance with Nasdaq listing rules?

Tevogen Bio regained compliance with Nasdaq Listing Rule 5450(a)(1) by implementing a 1-for-50 reverse stock split of its common stock, effective March 6, 2026, which raised the per-share trading price above Nasdaq’s minimum bid price threshold.

When did Nasdaq confirm Tevogen Bio (TVGN) is back in bid-price compliance?

Nasdaq sent Tevogen Bio a written notification on March 20, 2026, confirming the company had regained compliance with the minimum bid price requirement for continued listing on the Nasdaq Global Market and indicating that the compliance matter is closed.

What was the reverse stock split ratio for Tevogen Bio (TVGN)?

Tevogen Bio implemented a 1-for-50 reverse stock split of its common stock. For every 50 pre-split shares, shareholders now hold one post-split share, helping increase the market price per share to satisfy Nasdaq’s minimum bid price requirement.

On which Nasdaq markets and symbols does Tevogen Bio stock trade?

Tevogen Bio’s common stock trades on The Nasdaq Global Market under the symbol TVGN. Its warrants, each exercisable for one share of common stock at $11.50 per share, trade on the same market under the symbol TVGNW.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/25/2026 - 05:04 PM EDT Learn about SEC filing dates

false 0001860871 0001860871 2026-03-20 2026-03-20 0001860871 TVGN:CommonStockParValue0.0001PerShareMember 2026-03-20 2026-03-20 0001860871 TVGN:WarrantsEachExercisableForOneShareOfCommonStockFor11.50PerShareMember 2026-03-20 2026-03-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 20, 2026

Tevogen Bio Holdings Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-41002		98-1597194
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

15 Independence Boulevard, Suite #210
Warren, New Jersey		07059
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (877) 838-6436

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.0001 per share		TVGN		The Nasdaq Stock Market LLC
Warrants, each exercisable for one share of Common Stock for $11.50 per share		TVGNW		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 20, 2026, Tevogen Bio Holdings Inc. (the “Company”) received written notice (the “Notification Letter”) from The Nasdaq Stock Market LLC notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5450(a)(1) for continued listing on The Nasdaq Global Market. Accordingly, the matter is now closed. The Notification Letter was sent following the implementation of a 1-for-50 reverse stock split of the Company’s common stock (the “Reverse Split”), which became effective on March 6, 2026. Additional information regarding the Reverse Split can be found in the Company’s Current Report on Form 8-K filed on March 4, 2026.

2

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Tevogen Bio Holdings Inc.
Date: March 25, 2026	By:	/s/ Ryan Saadi
	Name:	Ryan Saadi
	Title:	Chief Executive Officer

3

Filing Exhibits & Attachments

4 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.7 KB
• EX-101 XBRL DEFINITION FILE 26.1 KB
• EX-101 XBRL LABEL FILE 36.0 KB
• EX-101 XBRL PRESENTATION FILE 24.7 KB